Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
16
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Theriva Biologics Inc market cap is $6.61M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Theriva Biologics Inc 52 week high is $0.492 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Theriva Biologics Inc 52 week low is $0.136 as of November 17, 2026.
Theriva Biologics Inc stock price today is $0.14.
Theriva Biologics Inc stock price yesterday was $0.1441.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Theriva Biologics Inc's P/E ratio is -0.56.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Theriva Biologics Inc P/B ratio is 0.5975.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Theriva Biologics Inc 50-day moving average is $0.2066.